Valentina Pecoraro1, Elena De Santis2, Alessandra Melegari3, Tommaso Trenti4. 1. Department of Laboratory Medicine and Pathology, Azienda USL-University Hospital of Modena, Ospedale Civile S. Agostino Estense, Via Giardini 1355, Modena 41126, Italy; Laboratory of Regulatory Policies, IRCCS - "Mario Negri" Institute of Pharmacological Research, Milan, Italy. Electronic address: valepecoraro@gmail.com. 2. Department of Laboratory Medicine and Pathology, Azienda USL-University Hospital of Modena, Ospedale Civile S. Agostino Estense, Via Giardini 1355, Modena 41126, Italy. Electronic address: elena.desantis83@gmail.com. 3. Department of Laboratory Medicine and Pathology, Azienda USL-University Hospital of Modena, Ospedale Civile S. Agostino Estense, Via Giardini 1355, Modena 41126, Italy. Electronic address: a.melegari@ausl.mo.it. 4. Department of Laboratory Medicine and Pathology, Azienda USL-University Hospital of Modena, Ospedale Civile S. Agostino Estense, Via Giardini 1355, Modena 41126, Italy. Electronic address: t.trenti@ausl.mo.it.
Abstract
BACKGROUND: Monoclonal antibodies drugs directed against TNFα, TNFα inhibitors, are immunogenic, and consequent anti-drug antibodies (ADA) formation may decrease the functional drug concentration, resulting in a loss of response. We evaluated the impact of ADA on TNFα therapeutic response. METHODS: We considered studies enrolling adult patients affected by autoimmune inflammatory disease in therapy with TNFα inhibitors. We collected data about study and population characteristics, treatment dosage, determination of ADA and adverse events (AE). We combined data in meta-analysis, calculating risk ratios (RR) for each study. p-Values<0.05 were considered as statistically significant. Methodological quality was evaluated. Analyses were performed with the STATA 11 and RevMan 5.3 softwares. RESULTS: We included 34 studies enrolling 4273 patients. Of these, 794 (18.6%) developed ADA. Our analysis showed a significant reduction of response (RR 0.43, 95%CI 0.3-0.63) in patients with ADA respect to patients without, especially in patients treated with Infliximab (RR 0.37) or Adalimumab (RR 0.40). Furthermore, the administration of TNFα inhibitors produced a reaction at the infusion site in 17%, infection in 30% and serious AE in 5% of patients. CONCLUSION: Detectable ADA significantly reduced TNFα inhibitors response. Drug administration can also cause injection site reaction and infections. Early detection of serum ADA levels may improve patients' management. Currently, there are many indications about the use of immunogenicity tests to guide the therapy, but information regarding how to implement it in clinical practice is needed.
BACKGROUND: Monoclonal antibodies drugs directed against TNFα, TNFα inhibitors, are immunogenic, and consequent anti-drug antibodies (ADA) formation may decrease the functional drug concentration, resulting in a loss of response. We evaluated the impact of ADA on TNFα therapeutic response. METHODS: We considered studies enrolling adult patients affected by autoimmune inflammatory disease in therapy with TNFα inhibitors. We collected data about study and population characteristics, treatment dosage, determination of ADA and adverse events (AE). We combined data in meta-analysis, calculating risk ratios (RR) for each study. p-Values<0.05 were considered as statistically significant. Methodological quality was evaluated. Analyses were performed with the STATA 11 and RevMan 5.3 softwares. RESULTS: We included 34 studies enrolling 4273 patients. Of these, 794 (18.6%) developed ADA. Our analysis showed a significant reduction of response (RR 0.43, 95%CI 0.3-0.63) in patients with ADA respect to patients without, especially in patients treated with Infliximab (RR 0.37) or Adalimumab (RR 0.40). Furthermore, the administration of TNFα inhibitors produced a reaction at the infusion site in 17%, infection in 30% and serious AE in 5% of patients. CONCLUSION: Detectable ADA significantly reduced TNFα inhibitors response. Drug administration can also cause injection site reaction and infections. Early detection of serum ADA levels may improve patients' management. Currently, there are many indications about the use of immunogenicity tests to guide the therapy, but information regarding how to implement it in clinical practice is needed.
Authors: Matthew D Rockstrom; Liangyu Chen; Ping Taishi; Joseph T Nguyen; Cody M Gibbons; Sigrid C Veasey; James M Krueger Journal: Sleep Med Rev Date: 2017-11-17 Impact factor: 11.609
Authors: Silvia Sirotti; Elena Generali; Angela Ceribelli; Natasa Isailovic; Maria De Santis; Carlo Selmi Journal: Auto Immun Highlights Date: 2017-07-12
Authors: Laura Magill; Marsilio Adriani; Véronique Berthou; Keguan Chen; Aude Gleizes; Salima Hacein-Bey-Abina; Agnes Hincelin-Mery; Xavier Mariette; Marc Pallardy; Sebastian Spindeldreher; Natacha Szely; David A Isenberg; Jessica J Manson; Elizabeth C Jury; Claudia Mauri Journal: Front Immunol Date: 2018-12-05 Impact factor: 7.561
Authors: Patricia Romero-Cara; Daniel Torres-Moreno; José Pedregosa; Juan Antonio Vílchez; María Sergia García-Simón; Guadalupe Ruiz-Merino; Senador Morán-Sanchez; Pablo Conesa-Zamora Journal: Int J Med Sci Date: 2018-01-01 Impact factor: 3.738
Authors: Mark C Genovese; Josephine Glover; Maria Greenwald; Wieslawa Porawska; Elias Chalouhi El Khouri; Eva Dokoupilova; Juan Ignacio Vargas; Mykola Stanislavchuk; Herbert Kellner; Elena Baranova; Nobuhito Matsunaga; Rieke Alten Journal: Arthritis Res Ther Date: 2019-12-12 Impact factor: 5.156